TG Therapeutics, Inc. Stock News

Insurance stock Root soared to a new high on Friday. The IBD 50 holding has an ideal Composite and Relative Strength Rating.

Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer and autoimmune disorders. TG Therapeutics' BRIUMVI achieved significant sales growth in 2024, supporting positive cash flow and funding for future developments, including azer-cel for autoimmune disord...

TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient c...

TGTX's Briumvi, despite initial struggles, has shown strong performance by consistently beating earnings estimates, even with competition from Roche's Zunovo. Briumvi's competitive advantages include a shorter infusion time, lower malignancy risks, and a more favorable price compared to Ocrevus. TGTX's financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring a...

Biotech stock TG Therapeutics is outperforming the major indexes in a declining stock market. TGTX stock hit a new high on Friday.

These watch list stocks have beenholding near buy points while the market has been breaking down. The post S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout appeared first on Investor's Business Daily.

Following news of an estimates-topping fourth quarter, TG Therapeutics (TGTX 9.24%) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market Intelligence, as of mid-afternoon Friday, the biotech's share price had risen by almost 27% week to date.

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting, being held April 5 - 9, 2025, in San Diego, California. Abstracts are now available online an...